Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00354367|
Recruitment Status : Withdrawn
First Posted : July 20, 2006
Last Update Posted : May 28, 2012
|Condition or disease||Intervention/treatment||Phase|
|Crohn Disease||Drug: Certolizumab pegol||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IIIB Multicenter, Open Label, Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor (TNF) in Crohn's Disease Patients With Draining Fistulas.|
|Study Start Date :||January 2007|
- Investigation of Clinical efficacy of certolizumab pegol for fistula closure, as measured by the proportion of patients with fistula improvement after 16 weeks of treatment.
- Investigation of Clinical efficacy of certolizumab pegol for maintenance of fistula closure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354367
|Study Director:||Krassimir Mitchev, MD||UCB / Global Medical Affairs|